Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they represent the second or third line in neuropathic pain, that remain difficult to manage. Moreover, these drugs show several side effects that limit their use. In addition, opioids possess addictive properties that are associated with misuse and drug abuse. Among available opioids compounds, buprenorphine has been suggested advantageous for a series of clinical reasons, including the effectiveness in neuropathic pain. Some properties are partly explained by its unique pharmacological characteristics. However, questions on the dynamic profile remain to be answered. Pharmacokinetics optimization strategies, and additional potentialities, are still to be explored. In this paper, we attempt to conceptualize the potential undiscovered dynamic profile of buprenorphine.

Buprenorphine. Far beyond the “ceiling” / Infantino, R.; Mattia, C.; Locarini, P.; Pastore, A. L.; Maione, S.; Luongo, L.. - In: BIOMOLECULES. - ISSN 2218-273X. - 11:6(2021), pp. 1-8. [10.3390/biom11060816]

Buprenorphine. Far beyond the “ceiling”

Mattia C.;Locarini P.;Pastore A. L.;Luongo L.
2021

Abstract

Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they represent the second or third line in neuropathic pain, that remain difficult to manage. Moreover, these drugs show several side effects that limit their use. In addition, opioids possess addictive properties that are associated with misuse and drug abuse. Among available opioids compounds, buprenorphine has been suggested advantageous for a series of clinical reasons, including the effectiveness in neuropathic pain. Some properties are partly explained by its unique pharmacological characteristics. However, questions on the dynamic profile remain to be answered. Pharmacokinetics optimization strategies, and additional potentialities, are still to be explored. In this paper, we attempt to conceptualize the potential undiscovered dynamic profile of buprenorphine.
2021
biased agonist; buprenorphine; chronic pain; protean agonist
01 Pubblicazione su rivista::01a Articolo in rivista
Buprenorphine. Far beyond the “ceiling” / Infantino, R.; Mattia, C.; Locarini, P.; Pastore, A. L.; Maione, S.; Luongo, L.. - In: BIOMOLECULES. - ISSN 2218-273X. - 11:6(2021), pp. 1-8. [10.3390/biom11060816]
File allegati a questo prodotto
File Dimensione Formato  
Infantino_Buprenophrine_2021.pdf

accesso aperto

Note: https://doi.org/10.3390/biom11060816
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 222.46 kB
Formato Adobe PDF
222.46 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1555955
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 10
social impact